Following the successful closing of its Phase 3 OPTIMIZE Trial for OCS-01, Oculis is set for the next phase. If approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
